It can be observed that the use of the optimal cut-off value of the ABCA13 ELISA (3.67 ng/mL) with the higher diagnostic value would allow an advance in infection eradication to 6 years from program start (>70% reduction) with just an 54% decrease in the benefit/cost ratio (0.45 vs. 0.98) compared to the antibody ELISA. The gene discussed is ABCA13; the disease is infection.